Imatinib cytotoxicity in ACE2-expressing cells
Corresponding Organization :
Other organizations : Weizmann Institute of Science, Israel Institute for Biological Research
Variable analysis
- Imatinib (Novartis®) at increasing concentrations
- Camostat (Tocris®) at reported doses
- E64d (Caymanchem) at reported doses
- Cell viability measured using the XTT cell proliferation kit (Biological Industries®)
- Cell lines: VeroE6 or HEK293T-hACE2 cells
- Seeding density: 4000 or 8000 cells/well of 96-well plate
- Treatment duration: 8 h for Imatinib
- Positive control: Not explicitly mentioned
- Negative control: Not explicitly mentioned
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!